Skip to content
OpenCapital
Get started

Cumberland Pharmaceuticals CPIX Q1 2026 earnings

Reported May 5, 2026 · Before market open

Revenue$9.1MBeat by $628.3K
EPS-$0.13In line
Revenue estimate$8.5M
EPS estimate-$0.13

Next report

Aug 4, 2026 (In 6 days)
Revenue estimate$8.5M
EPS estimate-$0.13

Financials

Q1 2026

Income statement

See full
Revenue$9.1M-22.0%
Gross profit$7.2M-30.0%
Operating income-$3.1M-342%
Net income-$3.3M-362%
EPS (diluted)-$0.22-375%

Balance sheet

See full
Cash & equivalents$11.0M-27.1%
Total debt$4.8M-7.1%
Total equity$21.6M-24.5%
Total assets$71.0M+1.5%

Cash flow

See full
Operating cash flow$387.0K-90.1%
CapEx--100%
Free cash flow$387.0K-89.9%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$105.33M+102%
Enterprise value$99.15M+141%
P/S2.5×+1.3×

Profitability

See full
Gross margin82.9%-1.4pp
Operating margin-17.2%-125pp
Net margin-17.6%-103pp
FCF margin3.3%—

Returns & leverage

See full
Return on equity-29.4%-86.3pp
Debt / equity0.2×0.0×
Current ratio1×-0.3×

Segments

By product

See full
Sancuso$2.9M+29.8%
Vibativ$2.1M-29.4%
Talicia$1.9M—
Other revenue$168.9K-94.6%

Versus estimates

Revenue

Q1 2026$9.1MBeat by $628.3K
Q4 2025$13.7MBeat by $5.2MQ3 2025$8.3MQ2 2025$10.8MQ1 2025$11.7MQ4 2024$10.4M

Diluted EPS

Q1 2026-$0.13In line
Q4 2025-$0.01Beat by $0.12Q3 2025-$0.06Q2 2025$0.02Q1 2025$0.16Q4 2024-$0.02

Ask the moment Cumberland Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Cumberland Pharmaceuticals report Q1 2026 earnings?
Cumberland Pharmaceuticals (CPIX) reported Q1 2026 earnings on May 5, 2026 before market open.
What were Cumberland Pharmaceuticals's Q1 2026 revenue and EPS?
Cumberland Pharmaceuticals reported revenue of $9.1M and eps of $-0.13 for Q1 2026.
Did Cumberland Pharmaceuticals beat estimates in Q1 2026?
Revenue beat the consensus estimate of $8.5M by $628.3K. EPS beat the consensus estimate of $-0.13 by $0.00.
How did Cumberland Pharmaceuticals's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 22.0% from $11.7M a year earlier.
Where can I find Cumberland Pharmaceuticals's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001087294-26-000046) and the 10-Q periodic report (0001087294-26-000049) directly on SEC EDGAR. The filing index links above go to sec.gov.